Niroj Mali

Dr. Niroj Mali

Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
NMNiroj Mali
Niroj Mali
FSFeng Su
Feng Su
JGJie Ge
Jie Ge
WFwenxing fan
wenxing fan
JZJing Zhang
Jing Zhang
JMJingYuan Ma
JingYuan Ma
Background: The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients. Methods: Eight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 software were used for analyses and plotting. Results: A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF–α, IL-6). However, there was no significant difference in BUN and eGFR between the experimental group and the control group. Conclusions: Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.

18 November 2022 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
CLChangYan Li
ChangYan Li
JMJingYuan Ma
JingYuan Ma
NMNiroj Mali
Niroj Mali
LZLe Zhang
Le Zhang
TWTao Wei
Tao Wei
JYJing Yang
Jing Yang
Background: A chronic inflammatory disease caused by disturbances in metabolism, diabetic nephropathy (DN) is a chronic inflammatory disease. Pyroptosis is a novel form of programmed cell death in many inflammation-related diseases, including DN. Therefore, pyroptosis could be a promising target for DN therapy. Methods: To get the components and pharmacodynamic targets of Chuanxiong, we identified by searching TCMID, TCMSP, ETCM and HERB databases. Then, from the Molecular Signatures Database (MSigDB) and Gene Ontology (GO) database, pyroptosis genes were collected. Identification of critical genes in DN by bioinformatics analysis and then using the ConsensusClusterPlus package to divide the express data of diff genes into some subgroups with different levels of pyroptosis; the WGCNA machine algorithm was used to simulate the mechanism Chuanxiong improving DN. Results: In this study, we found DHCR24, ANXA1, HMOX1, CDH13, ALDH1A1, LTF, CHI3L1, CACNB2, and MTHFD2 interacted with the diff genes of DN. We used GSE96804 as a validation set to evaluate the changes of APIP, CASP6, CHMP2B, CYCS, DPP8, and TP53 in four different cell proapoptotic states. WGCNA analysis showed that DHCR24, CHI3L1, and CACNB2 had significant changes in different cell proapoptotic levels. In the experimental stage, we also confirmed that the active ingredients of Chuanxiong could improve the inflammatory state and the levels of pyroptosis under high glucose. Conclusion: The improvement of DN by Chuanxiong is related to the change of pyroptosis.

1 January 2022 in Archives of Nephrology and Urology
Verified
Journal Article
Open access
PDF file
NMNiroj Mali
Niroj Mali
JGJie Ge
Jie Ge
FSFeng Su
Feng Su
CLChangYan Li
ChangYan Li
WFWenXing Fan
WenXing Fan
This article reviews the iatrogenic (nutrient loss caused by dialysis, inflammatory reaction caused by dialysis, insufficient dialysis, and metabolic acidosis) and noniatrogenic (patients' insufficient diet, taste change, poor appetite, and psychosocial function) risk factors for malnutrition in maintenance hemodialysis patients. The aim of this review article is to incorporate these aspects into the malnutrition risk assessment of maintenance hemodialysis patients in order to enhance nutritional status, improve medical quality, and assure patient safety.

11 January 2023 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
CLChangYan Li
ChangYan Li
FSFeng Su
Feng Su
LZLe Zhang
Le Zhang
FLFang Liu
Fang Liu
ZLZhen Li
Zhen Li
NMNiroj Mali
Niroj Mali
Aim: Chuanxiong diabetic nephropathy, network pharmacology, molecular docking, NCOA1, NCOA2, diabetic nephropathy (DN), ACEI/ARB. Background: The development of network pharmacology promotes the process of medicinal transformation of traditional Chinese medicine. This study took Chuanxiong as an example to analyze the active components in the treatment of DN. Objective: Molecular docking and other technologies have effectively helped the complex find the disease's active ingredients. Methods: The data of Chuanxiong was collected from the TCPSP database, DN gene expression data were collected through the NCBI database, and DN-related genes were obtained through differential analysis. In addition, the regulatory network of Chuanxiong and the main active components of DN treatment was constructed using String and Cytoscape tools. At the same time, PPI network interaction analysis was performed on core genes and GO. KEGG analysis was performed to predict essential genes using the Auto Dock tool. Results: Eight active components of Chuanxiong were screened out. NCOA1 and NCOA2 could interact with Angelica lactone A, Myricetin, Chrysophanol, Chuanxiong, naphthalize, and Chrysophanol. Meanwhile, Angelica Lactone A, Myricetin, Chrysophanol, Chuanxiong, naphthafunolide, and Chrysophanol can affect the regulation of estrogen signaling pathway, endocrine and other factors regulating calcium reabsorption and adipogenesis of adipocytes through the regulation of steroid hormone stimulation and regulation of cAMP-dependent protein kinase complex. Conclusion: NCOA1 and NCOA2 can be used as pharmacodynamic targets of Chuanxiong for improving DN.

14 February 2022 in Tropical Journal of Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
WFWenXing Fan
WenXing Fan
SHShiJun Hong
ShiJun Hong
TWTao Wei
Tao Wei
YYYueNa Yang
YueNa Yang
MWMin Weng
Min Weng
NMNiroj Mali
Niroj Mali
Purpose: To investigate the effects of cannabinoid ligand in diabetic nephropathy mediated by streptozotocin (STZ) injection in rats. Methods: Rats deprived of food were injected streptozotocin (STZ, 70 mg/kg) followed by confirmation of diabetes by checking the blood glucose level for three consecutive days. The kidney tissue was exposed to periodic acid Schiff reagent (PASR) for the investigation of glomerular sclerotic injury under microscope. Results: Cannabinoid treatment decreased mesangial expansion, glomerular volume, proteinuria, reactive oxygen species and apoptosis in STZ rats. The cells were cultured with 40 mM of glucose for 8 h in which the podocytes responded with 2.9-fold increase in dihydroethidium fluorescence signal, compared to the podocytes cells cultured in low glucose (10 mM). However, cannabinoid treatment decreased ROS production in podocytes as indicated by dihydroehidium relative fluorescence. Further, the effect of ROS production by glucose on podocytes was inhibited by NADPH oxidase inhibitor, DPI (10 mM). Moreover, cannabinoid treatment reduced the expression of Sgk1, NADPH oxidase activity which was elevated by high glucose. Conclusion: Treatment with cannabinoid decreases mesangial expansion, glomerular volume, proteinuria, and reactive oxygen species production in STZ rats. Thus, cannabinoid may be a protective agent against diabetic nephropathy in humans.

1 October 2022 in Clinical Nephrology
Verified
Journal Article
Closed access
JGJie Ge
Jie Ge
NMNiroj Mali
Niroj Mali
LZLe Zhang
Le Zhang
ZLZhen Li
Zhen Li
WFwenxing fan
wenxing fan
Background: Previous evi-dence suggests that acute kidney injury (AKI) is common in patients with COVID-19 and associated with adverse outcomes. Moreover, the incidence and mortality of AKI in Asia are ambiguous. Objective: Evalu-ating the risk factors and risk of death from AKI in COVID-19 patients in Asia. Materi-als and methods: We conducted a meta -analysis of clinical observational studies of COVID-19 patients in Asia. Outcome mea-sures included: AKI in COVID-19 patients, overall mortality in COVID-19 patients, and mortality assessment in patients with AKI. The random-effects model was adopted, with heterogeneity and sensitivity analysis. Results: 27 clinical studies (18,216 Asian pa-tients with COVID-19) have been included in the study. The pooled incidence of AKI was 0.19 (95% CI 16 - 23%; I2 = 98.9%, p < 0.001); the pooled incidence of total mortality was 0.19 (95% CI 17 - 22%; I2 = 98.9%, p < 0.001). No publication bias was found (Egger's test, p = 0.396, 0.213). The pooled mortality in AKI patients with COVID-19 was 50% (95% CI 33 - 67%; I2 by random-effects model = 98.4%, p < 0.001). AKI was found to be a risk factor for death in stepwise regres-sion analysis; age, diabetes, and hyperten-sion were influencing factors for AKI risk in COVID-19 patients. Conclusion: AKI is a com-mon complication in Asian COVID-19 pa-tients, and it is associated with an increase in mortality of Asian COVID-19 patients. Any treatment that protects the kidney may be a practical intervention to reduce the mortal-ity of COVID-19 patients in Asia.